The goal of the NHLBI GO Exome Sequencing Project (ESP) is to discover novel genes and mechanisms contributing to heart, lung and blood disorders by pioneering the application of next-generation sequencing of the protein coding regions of the human genome across diverse, richly-phenotyped populations and to share these datasets and findings with the scientific community to extend and enrich the diagnosis, management and treatment of heart, lung and blood disorders. The groups participating and collaborating in the NHLBI GO ESP include:
  • Seattle GO - University of Washington, Seattle, WA
  • BroadGO - Broad Institute of MIT and Harvard, Cambridge, MA
  • WHISP - Ohio State University Medical Center, Columbus, OH
  • Lung GO - University of Washington, Seattle, WA
  • WashU GO - Washington University, St. Louis, MO
  • Heart GO - University of Virginia Health System, Charlottesville, VA
  • ChargeS GO - University of Texas Health Sciences Center at Houston
The group includes some of the largest well-phenotyped populations in the United States, representing more than 200,000 individuals altogether from the:
  • Women's Health Initiative (WHI)
  • Framingham Heart Study (FHS)
  • Jackson Heart Study (JHS)
  • Multi-Ethnic Study of Atherosclerosis (MESA)
  • Atherosclerosis Risk in Communities (ARIC)
  • Coronary Artery Risk Development in Young Adults (CARDIA)
  • Cardiovascular Health Study (CHS)
  • Lung Health Study (LHS)
  • COPD Genetic Epidemiology (COPDGene)
  • Severe Asthma Research Project (SARP)
  • Pulmonary Arterial Hypertension (PAH)
  • Acute Lung Injury (ALI)
  • Cystic Fibrosis (CF)
  • PennCATH
  • Cleveland Clinic Genebank
  • Massachusetts General Hospital Premature Coronary Artery Disease Study (MGH PCAD)
  • Heart Attack Risk in Puget Sound (HARPS)
  • Translational Research Underlying Disparities in Myocardial Infarction Patients' Health Status (TRIUMPH)